Novo Nordisk(US:NVO) ZACKS·2026-01-26 15:16Core Insights - Novo Nordisk (NVO) is a leading player in the cardiometabolic market, primarily driven by the success of its semaglutide-based drugs, Ozempic and Wegovy, which generated DKK 152.5 billion in the first nine months of 2025, accounting for approximately 66% of total sales [2][9] Product Performance - Ozempic and Wegovy have received multiple label expansions to enhance patient access and demand, with Wegovy approved for reducing major cardiovascular events and Ozempic being the only GLP-1 therapy approved for reducing kidney disease progression in T2D patients [3] - Despite the strong sales figures, sales of Ozempic and Wegovy are expected to face pressure in Q4 2025 due to slower-than-expected U.S. momentum and competition from unregulated compounded semaglutide products [4][9] - The oral semaglutide therapy Rybelsus, along with Novo Nordisk's insulin franchise and Rare Disease portfolio, is anticipated to provide additional revenue support during the period [5] Competitive Landscape - Eli Lilly (LLY) is a significant competitor in the diabetes and obesity market, with its tirzepatide-based drugs, Mounjaro and Zepbound, generating combined sales of $24.8 billion in the first nine months of 2025, representing 54% of LLY's total revenues [6] - Lilly is expected to report strong financial results driven by demand for its GLP-1 drugs and expanding market presence [7] Regulatory Developments - Novo Nordisk received FDA approval for its oral Wegovy pill in late December, marking a significant milestone as the first oral GLP-1 RA for weight management, which is expected to enhance sales in 2026 [8] - Eli Lilly is also pursuing regulatory approval for its oral GLP-1 pill, orforglipron, which is currently under FDA review [8] Market Trends - The obesity market has gained attention due to its substantial growth potential, with smaller biotech firms like Viking Therapeutics developing GLP-1-based therapies to compete with established players [10]